Epizyme launches dosing program
Updated: Feb 5, 2020
Epizyme announces first patient dosed in global clinical program. Dana Farber Cancer Institute and Cincinnati Children's Hospital are the first sites activated for pediatric enrollment.
The study of tazemetostat offers a possible treatment for INI1-negative tumors, including AT/RT, when no other treatments are available. Read More
